Interius BioTherapeutics raises $76M for GCT platform
Interius BioTherapeutics has raised $76 million in fundraising to advance its gene and cell therapy (GCT) platform. Read More
HelaPlex, Scispot.io to create life science digital workspace
HelaPlex and Scispot.io have partnered to create a fully digital life science coworking space. Read More
Akoya posts positive results in Q1
Spatial biology tools company Akoya Biosciences reported growth in revenues and gross profits for the first quarter of 2021. Read More
Imugene licenses CD19-expressing oncolytic virus from City of Hope
Immuno-oncology company Imugene has licensed patents from the City of Hope that pave the way for an immunotherapy for solid tumors that combines a CD19-expressing oncolytic virus with CD-19 chimeric antigen receptor T-cell therapy technology. Read More
G2 Bio Companies launch to develop genetic-based medicines
The G2 Bio Companies have launched to fund and develop gene therapy candidates from the University of Pennsylvania Gene Therapy Program. Read More
Gamma to acquire majority stake in Mirus Bio
Gamma Biosciences has purchased a controlling stake in Mirus Bio, a developer of lipid-polymer nanocomplexes for nucleic acid delivery. Read More
Clover highlights preclinical data for COVID-19 vaccine candidate
Clover Biopharmaceuticals said that its second-generation, protein-based COVID-19 vaccine candidate has demonstrated in preclinical testing that it can provide broad neutralization of the original SARS-CoV-2 strain as well as variants of concern. Read More
Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all adult age groups in a phase II study with 722 volunteers. Now the firms are advancing to a phase III study that is expected to start in the coming weeks. Read More
Merck, BioMed X extend collaboration in oncology, autoimmunity
Merck has extended its collaboration with German company BioMed X and will start six additional research projects at the BioMed X Institute. The projects will build on research in oncology and autoimmunity. Read More
MD Anderson, Refuge to develop next-gen cell therapies
The University of Texas MD Anderson Cancer Center is partnering with Refuge Biotechnologies to advance new cell therapies for the potential treatment of solid tumors. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
